Heredopathia atactica polyneuritiformis phytanic-acid storage disease, Refsum's disease:" a biochemically well-defined disease with a specific dietary treatment
- PMID: 6170281
- DOI: 10.1001/archneur.1981.00510100033003
Heredopathia atactica polyneuritiformis phytanic-acid storage disease, Refsum's disease:" a biochemically well-defined disease with a specific dietary treatment
Abstract
Heredopathia atactica polyneuritiformis (phytanic-acid storage disease, Refsum's disease) is an inborn error of metabolism, in which the body accumulates exogenous phytanic acid. The severe manifestations of this disease, which include pigmentary retinal degeneration, chronic polyneuropathy, ataxia, impaired hearing, and cardiopathy, can be either kept from worsening or reversed by elimination of foods rich in phytanic acid from patients' diets. This is borne out by a 20-year experience with two patients, whose conditions improved markedly once they stopped eating butter, animal fat, and other foods rich in phytanic acid.
Similar articles
-
[Heredopathia atactica polyneuritiformis. Hexadecanoic acid storage disease (Refsum's disease). Definition, treatment and pathogenesis. A short review].Psychiatr Neurol Med Psychol Beih. 1977;22-23:11-8. Psychiatr Neurol Med Psychol Beih. 1977. PMID: 95656 German.
-
Heredopathia atactica polyneurotiformis: therapeutic and pathogenetic aspects.Riv Patol Nerv Ment. 1976 Jun;97(3):115-26. Riv Patol Nerv Ment. 1976. PMID: 74082
-
[Heredopathia atactica polyneuritiformis: phytanic acid storage disease (Refsum's syndrome). Effect of diet therapy on retinal and cochlear changes].Neurol Neurochir Pol. 1984 Jan-Feb;18(1):1-4. Neurol Neurochir Pol. 1984. PMID: 6203044 Polish. No abstract available.
-
Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation.J Neurochem. 2002 Mar;80(5):727-35. doi: 10.1046/j.0022-3042.2002.00766.x. J Neurochem. 2002. PMID: 11948235 Review.
-
Phytanic acid storage disease (Refsum's disease): clinical characteristics, pathophysiology and the role of therapeutic apheresis in its management.J Clin Apher. 1999;14(4):181-4. doi: 10.1002/(sici)1098-1101(1999)14:4<181::aid-jca5>3.0.co;2-z. J Clin Apher. 1999. PMID: 10611628 Review.
Cited by
-
Neuroectodermal (CHIME) syndrome: an additional case with long term follow up of all reported cases.J Med Genet. 1995 Jun;32(6):465-9. doi: 10.1136/jmg.32.6.465. J Med Genet. 1995. PMID: 7666399 Free PMC article. Review.
-
Advances in genetics: what are the benefits for patients?J Med Genet. 2006 Jul;43(7):555-6. doi: 10.1136/jmg.2005.039966. Epub 2005 Dec 9. J Med Genet. 2006. PMID: 16339848 Free PMC article. Review. No abstract available.
-
Adrenoleukodystrophy: biochemical procedures in diagnosis, prevention and treatment.J Inherit Metab Dis. 1987;10 Suppl 1:46-53. doi: 10.1007/BF01812846. J Inherit Metab Dis. 1987. PMID: 3119941 Review.
-
Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome.J Inherit Metab Dis. 1995;18(4):435-47. doi: 10.1007/BF00710055. J Inherit Metab Dis. 1995. PMID: 7494402 Review.
-
Retinitis pigmentosa, pigmentary retinopathies, and neurologic diseases.Curr Neurol Neurosci Rep. 2006 Sep;6(5):403-13. doi: 10.1007/s11910-996-0021-z. Curr Neurol Neurosci Rep. 2006. PMID: 16928351 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources